Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

Anemia Clinical Trial

Official title:

Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02734641
• Other study ID #: 155-15EMC
• Status: Completed
• Start date: August 2016
• Est. completion date: April 17, 2018

Study information

• Verified date: December 2018
• Source: HaEmek Medical Center, Israel
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to examine whether iron therapy in patients with intravenous iron deficiency anemia causes an increase in appetite. And whether this increase is mediated by the hormone ghrelin.

Description:

Prior to Iron treatment Investigator will sample subject blood for: counting blood, iron sector indices, renal function, electrolytes, and measure the level of ghrelin fasting plasma. In addition, the patient will fill a structured questionnaire that examines appetite levels. participants will be asked to answer a structured questionnaire which will include information on demographics, clinical data (fever, allergies, weight, height) and comorbidities. Additional data on laboratory tests, comorbidities, medication and regular blood and urine cultures results will be taken from the medical file. Iron treatment will be given according to local standard procedure . At the end of the treatment ghrelin levels and questionaire will be retaken .

iron deficiency anemia is defined: hemoglobin <12 gr / dl in women and Hb <13 gr / dl in men with ferritin <15 ng / ml.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 111
• Est. completion date: April 17, 2018
• Est. primary completion date: April 1, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects

• sign and dated informed consent form.

Exclusion Criteria:

• chronic inflammatory disease.

• chronic renal failure

• active cancer.

• active Infectious disease.

• non iron deficiency anemia.

• pregnancy.

Related Conditions & MeSH terms

• Anemia

Locations

Country	Name	City	State
Israel	Haemek medical center	Afula

Sponsors (1)

Lead Sponsor	Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ghrelin levels after treatment with Intravenous Iron		12 weeks